Daniel Mizrahi
About Daniel Mizrahi
Daniel Mizrahi, age 51, has served as an independent director of Cryo-Cell International, Inc. since September 2021. His background includes CEO experience in Central America retail distribution, procurement leadership at a major Mexican tool company, and real estate asset management in Florida. He is designated independent by the Board under NYSE standards and serves on key board committees, including chairing Compensation; he attended at least 75% of board and applicable committee meetings in FY2024, and attended the 2024 Annual Meeting .
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| Power Tech, S.A. | Chief Executive Officer | 2012–present | Oversees operations serving 3,000+ retail clients in Central America |
| Cohesa, S.A. – Toolcraft | Director of Purchasing | 2008–2012 | Managed ~$60 million annual purchase budget |
| Maayan, LLC | Property Manager | 2003–2008 | Managed acquisition and operations of >500 residential units in Florida |
External Roles
| Organization | Role | Nature | Notes |
|---|---|---|---|
| Power Tech, S.A. | CEO | Overseas/private | Central America retail client network |
| Cohesa, S.A. – Toolcraft | Director of Purchasing (former) | Private | One of Mexico’s largest tool companies |
| Maayan, LLC | Property Manager (former) | Private | Real estate vehicle for foreign investors |
Board Governance
- Committee assignments: Audit Committee member; Compensation Committee Chair; Governance Committee member; Nominating Committee member .
- Independence: Board determined Mizrahi is independent per NYSE standards; Audit Committee comprised entirely of independent directors .
- Meetings/attendance: Board held 8 meetings in FY2024; each director attended at least 75% of board and relevant committee meetings; all directors attended the 2024 Annual Meeting .
- Committee activity: Audit Committee met 4 times; Compensation Committee met 1 time in FY2024 .
- Board leadership: Chairman is Co-CEO David Portnoy; the other Co-CEO is his brother, Mark Portnoy .
Fixed Compensation
| Year | Cash Retainer Policy ($) | Fees Earned or Paid in Cash ($) | Annual Option Grant (shares) | Option Awards ($) |
|---|---|---|---|---|
| FY2023 | 40,000 | 50,000 | 5,300 | 22,342 |
| FY2024 | 40,000 | 50,000 | 5,300 | 18,915 |
Notes:
- Non-employee director compensation structure: $40,000 annual retainer plus an annual stock option grant of 5,300 shares at fair market value on grant date .
- Actual cash fees reported were $50,000 in FY2023 and FY2024; the proxy does not itemize committee chair/member fees beyond the base retainer .
Performance Compensation
- The proxy discloses director equity as annual stock option grants (5,300 shares); no performance-based metrics (e.g., revenue, EBITDA, TSR) tied to director compensation are specified in the director section .
Other Directorships & Interlocks
| Company | Public Company? | Role | Potential Interlock/Conflict |
|---|---|---|---|
| Power Tech, S.A. | No disclosure of public listing | CEO | None disclosed with CCEL; historical consulting to CCEL on affiliates and outsourcing noted |
| Cohesa, S.A. – Toolcraft | No disclosure of public listing | Former Director of Purchasing | None disclosed |
| Maayan, LLC | Private | Former Property Manager | None disclosed |
- Related party transactions: Audit Committee determined no related party transactions other than the Portnoy family relationship (Co-CEOs are brothers) and accounting services provided by Audit Committee Chair Harold Berger to Mark Portnoy .
Expertise & Qualifications
- Commercial leadership across Central and South America distribution, large-scale procurement, and real estate operations .
- Governance roles include chairing Compensation and serving on Audit, Governance, and Nominating committees; Audit Committee independence and financial expertise designated to Harold Berger (CPA), not Mizrahi .
Equity Ownership
| Holder | Beneficially Owned Shares | Percent of Class | Options Exercisable or within 60 days |
|---|---|---|---|
| Daniel Mizrahi | 51,834 | <1% | 21,200 |
Notes:
- Percent calculations per SEC Rule 13d-3 using 8,055,150 shares outstanding as of 9/15/2025 plus in-the-money/exercisable options within 60 days .
- Section 16(a) filings reviewed by the company were timely based on the company’s assessment .
Shareholder Voting Signals
| Item (Oct 29, 2024 Annual Meeting) | For | Against | Abstain |
|---|---|---|---|
| Election of Daniel Mizrahi | 4,072,486 | 370,901 | — |
| Ratify Wipfli LLP (auditor) | 6,697,620 | 186 | 3,536 |
| Say-on-Pay (NEO compensation) | 4,152,942 | 287,390 | 3,055 |
Governance Assessment
- Strengths:
- Independent status and multi-committee engagement; chairs Compensation, supporting oversight of executive pay and incentive programs .
- Strong shareholder support in director election and overall say-on-pay results at 2024 meeting, indicating investor confidence in board oversight .
- Audit Committee independence; financial expert designated (Berger), and regular committee activity (4 meetings) .
- Watch items and potential RED FLAGS:
- Board leadership concentration: Chairman is also Co-CEO, and Co-CEOs are brothers—raises inherent governance risk on independence and oversight; heightens importance of robust independent director challenge (including Mizrahi’s role) .
- Historical consulting by Mizrahi to Cryo-Cell on affiliates and outsourcing over the last decade—while the Audit Committee reports no related party transactions above disclosure thresholds, continued vigilance on any new or ongoing engagements is warranted .
- Director compensation disclosure shows $50,000 fees vs. $40,000 base retainer policy; lack of explicit detail on committee chair/member fee breakdown slightly reduces transparency of director cash compensation components .